Company / Return on Equity (ROE)
Vistagen Therapeutics, Inc. Return on Equity (ROE) History
FY2018-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-73.8%
FY2023
5-year range
-1665.4% / -19.5%
FY2019-FY2023
Trend
-278.5%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Vistagen Therapeutics, Inc. reports negative total equity of -73.8% in FY2023. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-73.8% in FY2023.
Improved from -1665.4% to -73.8% over the past 5 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- +1591.6pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2023, return on equity (roe) decreased 278.5% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -7.17 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2023 | -73.8% | -278.5% |
| FY2022 | -19.5% | - |
| FY2021 | - | - |
| FY2018 | -1665.4% | - |
| FY2017 | - | - |
| FY2014 | - | - |
| FY2012 | - | - |
| FY2011 | - | - |
As of FY2023 · SEC 10-K · Updated Jun 28, 2026